OSR Holdings shares surge 25.47% after-hours as Vaximm AG signs licensing term sheet with BCM Europe AG, securing $20M upfront.

OSR Holdings surged 25.47% in after-hours trading following the announcement that its subsidiary, Vaximm AG, entered a non-binding licensing term sheet with BCM Europe AG for the VXM01 oral cancer therapy. The deal includes a $20M upfront payment, potential milestone payments totaling $815M, and a six-month exclusivity period to finalize terms. BCM Europe AG will act as a strategic financial intermediary, while Vaximm retains ownership of VXM01’s intellectual property. The substantial upfront and milestone payments, coupled with the strategic partnership, likely drove the sharp after-hours rally, reflecting investor optimism about the licensing potential and its financial implications for the company.